Endpoint Expands Imaging and Radiopharmaceutical Expertise with Dr. Derek Cissell

Endpoint Expands Imaging and Radiopharmaceutical Expertise with Dr. Derek Cissell

January 20, 2026

A board-certified veterinary radiologist, Dr. Derek Cissell brings deep experience in preclinical imaging, quantitative analysis, and radioligand therapy, strengthening Endpoint’s support across complex imaging-driven and radiopharmaceutical programs.

Endpoint Preclinical is pleased to welcome Dr. Derek Cissell, VMD, PhD, DACVR, to our Expert Network. With more than 15 years of experience spanning academia, CRO leadership, and independent consulting, Derek brings a rigorous, interpretation-focused approach to preclinical imaging. His work integrates anatomy, physiology, physics, and imaging science to help teams design studies, evaluate results, and avoid misinterpretation that can undermine downstream decisions.
View Derek’s Profile.

Derek has led and supported imaging programs using MRI, CT, PET, SPECT, ultrasound, radiography, and gamma counting across a wide range of therapeutic areas. In senior leadership roles at large discovery organizations, he oversaw imaging operations at multiple sites, directed laboratory relocations and equipment upgrades, authored and standardized imaging SOPs, and served as a primary scientific interface for sponsors. His experience includes hands-on image analysis as well as management of large, multidisciplinary imaging teams executing dozens of studies each year.

“My goal is to apply imaging science in a way that stays grounded in the biology and the study design,” says Derek. “When imaging is interpreted in context, it becomes even more powerful for guiding decisions, advancing the most promising candidates, and avoiding costly missteps later in development.”

A defining feature of Derek’s work is his emphasis on interpretation rather than isolated metrics. He evaluates imaging data in the context of study design, tracer or modality choice, and biological expectations, ensuring results are meaningful rather than purely quantitative. His expertise in gamma counting, including method development, quality assurance, and training, is particularly relevant for radiopharmaceutical and radioligand therapy programs where small sources of variation can have outsized effects on conclusions.

Derek has trained analysts, technicians, and scientists in image segmentation, quantitative workflows, and gamma counting best practices, and has delivered internal and external lectures on imaging modalities and analysis principles. Earlier in his career, he served as an Assistant Professor and clinical instructor, mentoring residents and graduate students and contributing to translational imaging research.

“Derek brings exactly the kind of imaging perspective our clients value,” says Cole McLarty, CEO of Endpoint Preclinical. “He understands the technical details, but more importantly, he understands how imaging data should be interpreted and used to make sound development decisions. His experience across imaging modalities and radiopharmaceutical workflows significantly expands our capabilities in this area.”

We’re excited to welcome Dr. Derek Cissell to Endpoint Preclinical.

Sign up for Endpoint News
Contact Endpoint Preclinical
Recent Articles
Sign up for Endpoint News
Contact Endpoint Preclinical
Recent Articles